Chapter 3 - Sporadic Pancreatic Cancer: Glucose Homeostasis and Pancreatogenic Type 3 Diabetes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F18%3A43918111" target="_blank" >RIV/00216208:11120/18:43918111 - isvavai.cz</a>

Výsledek na webu

<a href="https://doi.org/10.5772/intechopen.75740" target="_blank" >https://doi.org/10.5772/intechopen.75740</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.5772/intechopen.75740" target="_blank" >10.5772/intechopen.75740</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Chapter 3 - Sporadic Pancreatic Cancer: Glucose Homeostasis and Pancreatogenic Type 3 Diabetes

Popis výsledku v původním jazyce

Sporadic pancreatic cancer (SPC) has been frequently associated with impaired glucose homeostasis manifested by prediabetes, Type 2 diabetes or predominantly by T3c diabetes which develops as the first symptom of cancer. Pathogenic mechanisms in the development of T3c diabetes have not been fully elucidated although specific substances originating in the tumor cells are supposed to be the cause of β-cell dysfunction and insulin resistance. New biomarkers evaluated in patients with recent-onset diabetes are necessary for the early diagnosis of this tumor. Actual data characterizing risk factors, early symptoms, pathogenic mechanisms, biomarkers and structured programs in detection of SPC are described. A multidisciplinary team of primary care physicians, gastroenterologists, endoscopists, radiologists and pathologists should improve the prognosis of this malignant disease.

Název v anglickém jazyce

Chapter 3 - Sporadic Pancreatic Cancer: Glucose Homeostasis and Pancreatogenic Type 3 Diabetes

Popis výsledku anglicky

Sporadic pancreatic cancer (SPC) has been frequently associated with impaired glucose homeostasis manifested by prediabetes, Type 2 diabetes or predominantly by T3c diabetes which develops as the first symptom of cancer. Pathogenic mechanisms in the development of T3c diabetes have not been fully elucidated although specific substances originating in the tumor cells are supposed to be the cause of β-cell dysfunction and insulin resistance. New biomarkers evaluated in patients with recent-onset diabetes are necessary for the early diagnosis of this tumor. Actual data characterizing risk factors, early symptoms, pathogenic mechanisms, biomarkers and structured programs in detection of SPC are described. A multidisciplinary team of primary care physicians, gastroenterologists, endoscopists, radiologists and pathologists should improve the prognosis of this malignant disease.

Druh

C - Kapitola v odborné knize

CEP obor

—

OECD FORD obor

30204 - Oncology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název knihy nebo sborníku

Advances in Pancreatic Cancer

ISBN

978-1-78923-640-8

Počet stran výsledku

20

Strana od-do

53-72

Počet stran knihy

213

Název nakladatele

IntechOpen

Místo vydání

London

Kód UT WoS kapitoly

—